<< Back To HomeBackground Documents and Presentations, SAGE meeting of October 2016
Printable Copy |
|
Background Documents and Presentations, SAGE meeting of October 2016
Centre International de Conference Genève (CICG) - Salle 2 in Geneva, 18-20 October 2016
Background documents
For weblinks to background documents, go to
- SAGE Yellow Book - October 2016
pdf, 18.70Mb
- Meeting of the Strategic Advisory Group of Experts on immunization, April 2016 – conclusions and recommendations
pdf, 493kb
- SAGE tracking record of recommendations and action points
pdf, 515kb
- Immunization highlights 2015
pdf, 459kb
- Report of the AFRO Regional Immunization Technical Advisory Group Meeting, 5-8 July 2016, Brazzaville, Congo.
pdf, 926kb
- Ministerial conference on immunization in Africa
pdf, 3.64Mb
- Ad-hoc Virtual TAG Meeting 2016- XXIV Meeting of the Technical Advisory Group on Vaccine-preventable Diseases, 13 May 2016, Washington, DC, USA.
pdf, 442kb
- Immunization highlights 2015, Report of the WHO Regional Office for Europe
pdf, 3.47Mb
- How to respond to vocal vaccine deniers in public. Best practice guidance, EURO
pdf, 1.12Mb
- Seventh Meeting of the South-East Asia Regional Immunization Technical Advisory Group (SEAR-ITAG): Full report
pdf, 349kb
- 25th Meeting of the Technical Advisory Group on Immunization and Vaccine Preventable Diseases, 26-29 July 2016, Manila, Philippines: Full report
pdf, 1.38Mb
- Update on the 22-23 June 2016 Gavi Board Meeting
pdf, 60kb
- Review of decisions, Gavi Alliance Board Meeting, 22-23 June 2016, Geneva
pdf, 251kb
- Minutes of the Gavi Alliance Board Meeting, 22-23 June 2016, Geneva
pdf, 369kb
- Global Advisory Committee on Vaccine Safety (GACVS), 15-16 June 2016. WER 2016;91:341-348
pdf, 304kb
- Summary of GACVS reviews of HPV vaccines
pdf, 661kb
- Report from the World Health Organization´s Third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8-10th June 2016
pdf, 600kb
- Immunization and Vaccine-related Implementation Research Advisory Committee (IVIR-AC) summary of conclusions and recommendations, 30 May-1 June 2016 meeting. WER 2016;91:389-96
pdf, 317kb
Session: Report from IVB director
Session: Report from GAVI, the Vaccine Alliance
Session: Report from other advisory committees on immunization
Session: Report of activities from international immunization partners
There are no background documents for this session.
Session: Global polio eradication initiative
- SAGE Polio WG - notes from August 2016 meeting
pdf, 248kb
- Fractional-dose inactivated poliovirus vaccination campaign, Telangana state, India, June 2016. WER 2016; 91:397–404
pdf, 474kb
- Update on Vaccine-Derived Polioviruses — Worldwide, January 2015–May 2016. MMWR August 5, 2016 / 65(30);763–769
pdf, 220kb
- Cessation of Use of Trivalent Oral Polio Vaccine and Introduction of Inactivated Poliovirus Vaccine — Worldwide, 2016. MMWR (to be published) or WER version WER 2016;91:421-427
pdf, 6.24Mb
- 13th Independent Monitoring Board Report
- GAPIII Containment Certification Scheme
pdf, 536kb
This document is intended to replace the two pages of Annex 4 of GAPIII: WHO verification that certified poliovirus-essential facilities comply with GAPIII.
- Measles and Rubella Global Strategic Plan 2012-2020 Midterm Review
pdf, 1.96Mb
- WHO Policy Recommendation on Measles Second Dose (MCV2): Considerations for removing the criteria for introduction
pdf, 1.09Mb
- Measles and Rubella: Regional Progress Updates
pdf, 8.01Mb
- Measles vaccines: WHO position paper. WER 2009;84:349-60
pdf, 369kb
- Rubella vaccines: WHO position paper. WER 2011;86:301-16
pdf, 414kb
- Report of the SAGE Working Group on Maternal and Neonatal Tetanus Elimination and Broader Tetanus Prevention
pdf, 1.06Mb
- Evidence to recommendation tables and GRADE tables
pdf, 210kb
- Tetanus vaccine WHO position paper
pdf, 193kb
- Community-based strategies including tetanus vaccination for preventing neonatal and/or maternal tetanus: Review of published reviews
pdf, 512kb
- Vaccination schedules used for preventing neonatal and/or maternal tetanus and duration of vaccine-induced protection: Review of published reviews
pdf, 472kb
- Compilation of presentations delivered to SAGE WG on MNTE and broader tetanus prevention
pdf, 16.30Mb
- Draft 2016 Mid Term Review of the Global Vaccine Action Plan
pdf, 421kb
- 2016 GVAP secretariat report
pdf, 14.14Mb
- Regional vaccine action plans 2016 progress reports
pdf, 11.41Mb
- GVAP 2016 reports from seven priority countries
pdf, 3.34Mb
- 2016 immunization score cards
pdf, 6.85Mb
- Background summary, conclusions and recommendations on Hepatitis B containing vaccines
pdf, 4.56Mb
- Global burden of HBV-attributable liver cancer
pdf, 562kb
- Systematic review of safety and efficacy of childhood schedules using of hepatitis B containing vaccines
pdf, 7.96Mb
- Update of the review on seroprotection after recombinant hepatitis B vaccination among newborn infants
pdf, 600kb
- Literature review of the thermostability of hepatitis B containing vaccines
pdf, 1.25Mb
- Review of the barriers to implement the birth dose of hepatitis B
pdf, 824kb
- Hepatitis B: an updated systematic review of economic evaluations in low and middle income countries
pdf, 558kb
- Background paper: Schedules and strategies for human papillomavirus (HPV) immunization
pdf, 1.45Mb
- Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Global Health 2016; 4: e609–16
pdf, 480kb
- Anogenital warts: Incidence, prevalence, self-reported history & quality of life. Cochrane; September 2016
pdf, 3.84Mb
- Randomized controlled trials of human papillomavirus vaccines: Systematic reviews prepared by Cochrane Response, London, UK; September 2016
pdf, 6.59Mb
- Summary of evidence: Population-level impact and herd effects following papillomavirus immunization programmes: a systematic review and meta-analysis; CHU de Québec – Université Laval
pdf, 419kb
- Summary of evidence: Human Papilloma Virus (HPV) Vaccination: An updated systematic review of cost-effectiveness analyses. Monash University Malaysia
pdf, 636kb
- Modelling estimates of the incremental effectiveness & cost-effectiveness of HPV vaccination
pdf, 256kb
- Summary of GACVS reviews of HPV vaccines
pdf, 661kb
- Executive summary: Session on yellow fever vaccines
pdf, 78kb
- Global strategy to eliminate yellow fever epidemics (EYE)
pdf, 4.50Mb
- Fractional dose yellow fever vaccine as a dose-sparing option for outbreak response. WHO secretariat information paper, 20 July 2016
pdf, 1.26Mb
- Yellow fever mass vaccination campaign using fractional dose in Kinshasa
pdf, 134kb
- Short-term research priorities for dose-sparing of YF vaccine (Revised version 26 September 2016)
pdf, 98kb
- 6. Vaccines and vaccination against yellow fever. WHO position paper – June 2013. WER 203;88:269-84
pdf, 1.20Mb
Session: Measles and rubella elimination
Session: Maternal and neonatal tetanus elimination and overall tetanus prevention
Session: Global Vaccine Action Plan
Session: Hepatitis B vaccination
Session: HPV vaccines
Session: Yellow fever
Presentations
Session: Report from IVB director
- Global report including key updates and challenges from regions.
pdf, 6.11Mb
J.-M. Okwo-Bele
- Report from Gavi, the Vaccine Alliance.
pdf, 1.19Mb
A. Nguyen
- Report of the Global Advisory Committee on Vaccine Safety (GACVS)
pdf, 1.74Mb
R. Pless
- Product Development for Vaccines Advisory Committee (PDVAC)
pdf, 845kb
D. Kaslow
- Report of the Immunization and vaccines related implementation research advisory committee (IVIR-AC)
pdf, 1.16Mb
R. Breiman
- Bill and Melinda Gates Foundation (BMGF)
pdf, 1.72Mb
O. Levin
- World Bank
pdf, 5.68Mb
T. Palu
- Objective of the session and overview of Global Polio Eradication Initiative
pdf, 4.41Mb
M. Zaffran
- Updates on implementation of OPV2 withdrawal
pdf, 1.77Mb
D. Chang-Blanc
- Report from SAGE Polio WG
pdf, 2.17Mb
Y. AL-Mazrou
- Global measles and rubella update
pdf, 1.74Mb
P. Strebel
- Findings and recommendations of the Mid Term Review of the measles and rubella strategic plan 2012-2020
pdf, 566kb
W. Orenstein
- Measles second dose introduction criteria
pdf, 2.75Mb
N. Turner
- Update on the current MNTE strategy, achievements, successes and challenges including country experiences
pdf, 2.79Mb
A. Raza
- Broader tetanus prevention: Impact of current tetanus immunization programmes and need for acquiring broader tetanus prevention
pdf, 800kb
R. Steinglass
- Review of key conclusions and recommendations by the SAGE Working Group
pdf, 1.57Mb
K. Johansen
- The GVAP Secretariat Report 2016: Update on process, new indicators, actions taken by the secretariat in response to previous reports
pdf, 1.26Mb
T. Cherian
- Summary of GVAP implementation progress review and recommendations for corrective actions at the mid-term of the Decade of Vaccines
pdf, 2.12Mb
A. Cravioto
- Introduction and key questions for the session
pdf, 476kb
K. Johansen
- Hepatitis B infection -related disease burden, Immunogenicity and safety of hepatitis B vaccine schedules and thermostability of hepatitis B vaccines
pdf, 2.90Mb
F. de la Hoz Restrepo
- Observed and forecasted impact of different hepatitis B immunization schedules and strategies
pdf, 1.39Mb
J. Edmunds
- Conclusions and proposed recommendations for SAGE
pdf, 267kb
K. Johansen
- Introduction and key questions for the session
pdf, 345kb
A. Pollard
- Update on HPV vaccine introduction and programmatic perspective
pdf, 4.79Mb
I. Ogbuanu
- HPV-related disease burden and effects of different HPV immunization schedules and strategies
pdf, 3.58Mb
M. Ramsay
- Observed and forecast impact of different HPV immunization schedules and strategies
pdf, 1.48Mb
M. Brisson
- Conclusions and proposed recommendations for SAGE
pdf, 4.48Mb
A. Pollard
Session: GAVI
Session: Reports from other Advisory Committees on Immunization
Session: Report of activities from international immunization partners
Session: Polio eradication initiative
Session: Measles and rubella elimination
Session: Maternal and neonatal tetanus elimination and overall tetanus prevention
Session: Global Vaccine Action Plan (GVAP)
Session: Hepatitis B vaccination
Session: HPV vaccines
Session: Yellow fever
Part 1: Long term Yellow Fever strategy
Part 2: Options for emergency surge capacity